Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect
Résumé
Background Corticosteroids (CS) with or without adjuvant immunosuppressant agents are standard treatment for pemphigus vulgaris (PV). The efficacy of adjuvant therapies in minimizing steroid-related adverse events (AEs) is unproven. Objectives To utilize data collected in a French investigator-initiated, phase III, open-label, randomized controlled trial to demonstrate the efficacy and safety of rituximab and seek approval for its use in PV.
Origine : Fichiers éditeurs autorisés sur une archive ouverte
